GLP-1, Klotho, and Repurposed Antiparasitics in Cancer (2026): A Systems Biology Framework for Metabolic Oncology

By Editorial Team

Key Takeaways

  • GLP-1 drugs may reduce cancer-promoting metabolic signals

  • Klotho regulates aging and tumor-related pathways

  • Ivermectin and mebendazole show anti-cancer activity in preclinical models

  • Combined, they form a multi-layer metabolic oncology strategy

  • Clinical validation is still needed


Introduction: Beyond Chemotherapy

Cancer treatment is shifting from purely cytotoxic strategies toward systems-level metabolic control. Increasing evidence suggests tumors depend not only on genetic mutations, but also on:

  • Dysregulated glucose and insulin signaling

  • Chronic inflammation

  • Altered mitochondrial function

  • Aging-associated pathway breakdown

This has led to the rise of metabolic oncology—an approach that targets the environment cancer depends on.

Three emerging pillars in this space include:

  • GLP-1 receptor agonists (metabolic regulators)

  • The Klotho longevity axis (aging and signaling control)

  • Repurposed antiparasitic drugs (cellular stress induction)

🧠 Part 1: GLP-1 Agonists and Cancer Metabolism

Key drugs:

  • semaglutide (e.g., Ozempic)

  • tirzepatide (Mounjaro)

🔬 Mechanisms relevant to cancer

GLP-1 receptor agonists:

  • ↓ Insulin levels → reduces IGF-1 signaling

  • ↓ Blood glucose → limits tumor fuel

  • ↓ Inflammation → suppresses tumor-promoting cytokines

  • ↓ Body fat → lowers estrogen and metabolic signaling

👉 Why this matters:

Hyperinsulinemia is one of the most overlooked drivers of cancer progression.

Evidence snapshot

  • Observational data suggest lower cancer incidence in some GLP-1 users.

  • Strongest signals:

    • Colorectal cancer

    • Pancreatic cancer (early signals, still debated)

    • Breast cancer

⚠️ Still evolving:

  • No definitive RCT proving cancer survival benefit yet.


Part 2: Klotho — The Longevity Gatekeeper

What is Klotho?

Klotho is a circulating anti-aging protein hormone that regulates:

  • Insulin/IGF-1 signaling

  • Wnt/β-catenin pathway

  • Oxidative stress

  • Mineral metabolism

🔬 Anti-cancer mechanisms

Klotho exerts tumor-suppressive effects by:

  • Inhibiting IGF-1 receptor signaling

  • Suppressing Wnt-driven tumor growth

  • Reducing fibrosis and tumor microenvironment support

  • Enhancing cellular stress resistance

🧠 The key limitation

  • No approved Klotho therapy exists

  • Oral supplementation is ineffective

  • Current strategies focus on endogenous upregulation.

Instead of administering Klotho directly, advanced protocols aim to upregulate endogenous Klotho expression:

  • Resveratrol → increases Klotho gene expression (ScienceDirect)
  • Vitamin D optimization → linked to higher circulating Klotho (ScienceDirect)
  • Exercise (especially resistance training) → increases circulating Klotho
  • Metabolic therapies (e.g., GLP-1 analogs, metformin) → shown in preclinical data to enhance Klotho (PubMed)

🔗 Klotho and metabolic disease

Low Klotho is associated with:

  • Obesity

  • Diabetes

  • Chronic kidney disease

  • Accelerated aging

👉 Which directly overlaps with cancer risk profiles.

⚙️ Part 3: Antiparasitics as Repurposed Anti-Cancer Agents

Key drugs:

  • ivermectin

  • mebendazole

🔬 Mechanisms of action

Ivermectin:

  • Inhibits Wnt/β-catenin signaling

  • Disrupts mitochondrial respiration

  • Induces apoptosis and autophagy

Mebendazole:

  • Blocks microtubule formation

  • Inhibits angiogenesis

  • Targets cancer stem-like cells

🧾 Evidence status

  • Strong preclinical evidence

  • Limited human trials

  • Increasing interest in combination protocols.

  • Not standard-of-care oncology treatments.

Read More: A Critical Evidence Review of Antiparasitic Drugs in Cancer Care (2026 Update)

Part 4: The Synergy Model

🧩 Three-Layer Framework

1. Systemic Metabolic Layer

  • semaglutide / tirzepatide
    → Reduce insulin, glucose, inflammation

2. Longevity & Signaling Layer

  • Klotho axis
    → Regulates IGF-1, Wnt, oxidative stress

3. Cellular Stress Layer

  • ivermectin / mebendazole
    → Direct tumor disruption

🧠 Integrated Mechanism

  • GLP-1 improves the metabolic terrain
  • Klotho stabilizes signaling networks
  • Antiparasitics destabilize tumor cells

👉 Net effect:

  • ↓ Tumor growth signals

  • ↓ energy supply

  • ↑ cancer cell vulnerability

🧬 Part 5: Cancer Types Most Likely to Fit This Model

Strongest theoretical fit:

1. Colorectal cancer

  • Insulin-sensitive

  • Wnt-driven

  • Responsive to metabolic intervention

2. Pancreatic cancer

  • Highly metabolic

  • Insulin/IGF-1 driven

  • Poor prognosis → high need for novel approaches

3. Breast cancer (especially hormone-positive)

  • Influenced by insulin and adiposity

Moderate fit:

  • Prostate cancer

  • Liver cancer

  • Endometrial cancer

Weak fit:

  • Highly mutation-driven cancers (e.g., melanoma, some lung cancers)

⚠️ Part 6: Safety, Risks, and Reality Check

Key limitations:

  • No large-scale RCTs validating this combination

  • Drug interactions not fully studied

  • Dose optimization unclear

  • Long-term safety unknown

Specific concerns:

  • ivermectin → neurotoxicity at high doses

  • mebendazole → liver enzyme elevation

  • GLP-1 drugs → GI side effects, rare pancreatitis

Clinical positioning

This framework is best viewed as:

  • Hypothesis-generating

  • Mechanistically plausible

  • Not a replacement for standard oncology care

🧠 Part 7: Future Directions

What needs to happen next:

  • Combination clinical trials (GLP-1 + repurposed drugs)

  • Biomarker studies (Klotho levels vs outcomes)

  • Personalized metabolic oncology protocols

Emerging frontier:

“Metabolic reprogramming + aging pathway modulation” may become a fourth pillar of oncology, alongside:

  • Surgery

  • Chemotherapy

  • Immunotherapy and Targeted Therapy


Closing Insight

The future of cancer treatment may not depend on a single breakthrough drug—but on strategic combinations that reshape the biological environment cancer depends on.

GLP-1 therapies, Klotho biology, and repurposed antiparasitics sit at the intersection of this shift—promising, provocative, and still evolving.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more